A congressional committee is urging the federal government to reconsider its hiring and firing policies as they relate to workers who use marijuana in compliance with state laws.
The House Appropriations Committee made the recommendation in a report attached to a large-scale spending bill funding parts of the federal government for Fiscal Year 2020 that was released on Monday. That same legislation also includes a provision protecting banks that service cannabis businesses and deletes a longstanding rider prohibiting Washington, D.C. from using its local tax dollars to implement a system of legal marijuana sales.
The panel made its new recommendation to the U.S. Office of Personnel Management (OPM).
“Hiring Guidelines—The Committee encourages OPM to review its policies and guidelines regarding hiring and firing of individuals who use marijuana in states where that individual’s private use of marijuana is not prohibited under the law of the State. These policies should reflect updated changes to the law on marijuana usage and clearly state the impact of marijuana usage on Federal employment.”
Existing federal policy strictly prohibits marijuana usage for federal workers even in states that have enacted legalization.
But even while the committee report is adding the new encouragement for a legal-state carveout for cannabis, the bill itself maintains a provision stating that a federal agency can only receive funds under the legislation if it “has in place, and will continue to administer in good faith, a written policy designed to ensure that all of its workplaces are free from the illegal use, possession, or distribution of controlled substances by the officers and employees of such department, agency, or instrumentality.”
That language could potentially be amended as the bill makes it way through the legislative process.
“We’re proud to support any efforts to ensure that the successful cannabis reform efforts in states around the nation are able to be implemented in smooth and sensible manner,” Justin Strekal, political director of NORML, told Marijuana Moment. “The prospect of responsible adults being denied federal employment opportunities is counterproductive and disproportionally impacts the veterans community.”
“It is our hope that the final appropriations package maintain these provisions to give certainty to the increasing number of states that are ending the failed war on cannabis,” he said.
The report recommendation is in line with a piece of standalone legislation introduced in March by Reps. Charlie Crist (D-FL) and Don Young (R-AK) that would bar federal agencies from firing employees solely because they tested positive for THC if they live in a legal cannabis state. That bill has not yet been scheduled for any hearings or votes.
“Voters across the country are saying yes to legalization. It’s time for the federal government to catch up with the will of the people,” Crist said in a press release about the new appropriations moves. “For folks from all walks of life, veterans, seniors, people facing chronic pain or disabilities, cannabis is an incredible source of relief – and that legal commerce is providing an economic boost to our communities. You shouldn’t lose your job if you need cannabis to live a healthy, normal life, and companies shouldn’t be at risk of operating a cash-only business in this day and age.”
It’s time for the federal government to follow the will of the people when it comes to medical marijuana! Proud to have secured two major wins for medical cannabis users & businesses across the country. https://t.co/XJR34AKNpX pic.twitter.com/GaCIoYHp5R
— Rep. Charlie Crist (@RepCharlieCrist) June 10, 2019
Besides the employment section, the spending bill report also discusses the cannabis banking provision that made it into the base spending bill.
That provision states that none of the money appropriated through the bill “may be used to penalize a financial institution solely because the institution provides financial services to an entity that is a manufacturer, a produce, or a person that participates in any business or organized activity that involves handling marijuana, marijuana products, or marijuana proceeds” in a jurisdiction where it’s legal.
Standalone legislation to provide that protection is making headway in Congress. It was approved by the House Financial Services Committee in March. Last week, it was placed on the chamber’s Union Calendar and is expected to be taken up for a full floor vote in coming weeks. In the meantime, lawmakers are considering adding amendments to broaden its GOP appeal.
Missing from the report is a description of a rider that appeared in earlier versions of the appropriations bill, stipulating that Washington, D.C. isn’t allowed to spend local tax revenue to implement legal marijuana sales. That section was nixed from the draft legislation as introduced. If it doesn’t get put back in later in the legislative process, the path would be cleared for officials in the nation’s capital to move ahead with a local proposal to expand the city’s current noncommercial legal cannabis system.
The 116th Congress has seen numerous standalone cannabis reform bills introduced so far, but it seems that lawmakers are also increasingly interested in pursuing change though the appropriations process.
Several other House Appropriations Committee reports released so far this year include provisions aimed at expanding research into medical cannabis, establishing a regulatory framework for CBD, providing funds for the implementation of hemp regulations, addressing impaired driving and protecting military veterans from losing their benefits for working in the cannabis industry.
On Friday, Rep. Alexandria Ocasio-Cortez (D-NY) filed an amendment to a separate spending bill coming to the floor this week that would eliminate a provision blocking the use of federal funds for “any activity that promotes the legalization of any drug or other substance in Schedule I.” The purpose of the legislation is to lift barriers to research into the therapeutic potential of substances such as psilocybin and MDMA, a summary prepared by the congresswoman’s office says.
Rep. Lou Correa (D-CA) also introduced an amendment to that bill that would prevent the Department of Education from denying or limiting “any funding or assistance to institutions of higher education” as a punishment for allowing the use of medical cannabis in a legal marijuana state.
The House Rules Committee will decide on Monday whether those drug policy amendments will be allowed for votes by the full body.
That panel’s chairman, Rep. James McGovern (D-MA), had repeatedly criticized his Republican predecessor for blocking cannabis votes on the floor and pledged to take a different approach.
This story was updated to include comment from Crist.
Photo courtesy of Mike Latimer.
Feds Send Warning Letter To Another CBD Company Over Medical Claims
The Food and Drug Administration (FDA) and Federal Trade Commission (FTC) sent a warning letter to a Florida-based CBD company on Tuesday, alleging that the business made several unsanctioned claims about the therapeutic benefits of their products.
The federal agencies accused Rooted Apothecary of unlawfully asserting that their cannabidiol products could treat symptoms of conditions such as ADHD, Parkinson’s disease, ear aches, ADHD and autism. Those claims appeared on the company’s website and social media accounts, they said.
Certain products appeared to be marketed as dietary supplements, which FDA currently prohibits as it works to develop an alternative regulatory scheme for CBD.
“Cannabis and cannabis-derived compounds are subject to the same laws and requirements as FDA-regulated products that contain any other substance,” Acting FDA Commissioner Ned Sharpless said in a press release. “We are working to protect Americans from companies marketing products with unsubstantiated claims that they prevent, diagnose, treat, or cure a number of diseases or conditions.”
FDA and FTC have issued a joint warning letter to a company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease, among other conditions/diseases. https://t.co/tsn4SBiGzH pic.twitter.com/sG3wyURMDS
— Dr. Ned Sharpless (@FDACommissioner) October 22, 2019
We’ve sent numerous warning letters that focus on matters of significant public health concern to CBD companies, and these actions should send a message to the broader market about complying with FDA requirements.
— Dr. Ned Sharpless (@FDACommissioner) October 22, 2019
“We’ve sent numerous warning letters that focus on matters of significant public health concern to CBD companies, and these actions should send a message to the broader market about complying with FDA requirements,” he said. “As we examine potential regulatory pathways for the lawful marketing of cannabis products, protecting and promoting public health through sound, science-based decision-making remains our top priority.”
FTC’s complaint with the company is that it violated a law that requires businesses that advertise medical claims about their products to have “competent and reliable scientific evidence” to back them up, which could include human clinical trials. Making or exaggerating such claims through “a product name, website name, metatags, or other means” without proper evidence is also prohibited.
FTC and @US_FDA warn Florida company marketing CBD products about claims related to treating autism, ADHD, Parkinson’s, Alzheimer’s, and other medical conditions: https://t.co/cAbxPPcxk8 pic.twitter.com/GdlttyBgxv
— FTC (@FTC) October 22, 2019
Rooted Apothecary must respond to the agencies within 15 working days to explain what steps it’s taking to resolve the issues. If the company fails to do so, it is subject to legal action, including the possible seizure of its products or an injunction. It may also have to compensate customers.
FDA emphasized that CBD products—other than the prescription medication Epidiolex, for the treatment of intractable epilepsy—are not currently allowed. But it also reiterated that the agency is in the process of developing rules that could allow for the lawful marketing of the compound.
In April, FDA sent warning letters to three other CBD companies that it said was making unauthorized claims about the medical benefits of their products. FTC also submitted warning letters to three separate CBD companies for allegedly advertising misleading statements about their products last month.
These letters are examples of the agency’s use of enforcement discretion. Former FDA Commissioner Scott Gottlieb, who recently suggested that the federal government should be involved in regulating state marijuana programs, clarified in March that the agency is only going after companies that make especially misleading claims about their products.
Senate Majority Leader Mitch McConnell (R-KY), who championed a provision of the 2018 Farm Bill federally legalizing hemp and its derivatives, has urged FDA to clear a path for the lawful marketing of CBD products by using enforcement discretion while it develops an interim final rule. A bipartisan group of lawmakers made a similar request in a letter sent to the agency last month.
“The FDA is working quickly to further clarify our regulatory approach for products containing cannabis and cannabis-derived compounds like CBD while using all available resources to monitor the marketplace and protect public health by taking action as needed against companies,” FDA Principal Deputy Commissioner Amy Abernethy said.
FDA’s working quickly to further clarify our regulatory approach for products with cannabis/cannabis-derivatives like CBD while using all available resources to monitor the marketplace & protect public health by taking action as needed against companies. https://t.co/HB9IhG2qud
— Dr. Amy Abernethy (@DrAbernethyFDA) October 22, 2019
We are committed to advancing our regulation of these products through an approach that, in line with our mission, prioritizes public health, fosters innovation and promotes consumer confidence. We plan to provide an update on our progress in this area in the near future.
— Dr. Amy Abernethy (@DrAbernethyFDA) October 22, 2019
“We recognize that there is significant public interest in cannabis and cannabis-derived compounds; however, we must work together to fill in the knowledge gaps about the science, safety and quality of many of these products,” she said. “We are committed to advancing our regulation of these products through an approach that, in line with our mission, prioritizes public health, fosters innovation and promotes consumer confidence.”
Photo courtesy of Kimzy Nanney.
GOP Senator Links Medical Marijuana Claims To Tobacco Industry Advertisements
Sen. John Cornyn (R-TX) said on Tuesday that claims about the therapeutic potential of marijuana remind him of decades-old tobacco industry advertisements asserting that the product had medical benefits.
In a speech on the Senate floor, Cornyn discussed a hearing that the International Narcotics Control Caucus, which he co-chairs, will hold on Wednesday to explore the public health impacts of cannabis. He said it was especially important to hear from experts about the subject as more states legalize marijuana and members of Congress, as well as Democratic presidential candidates, push to end federal prohibition.
Senate Hearing To Focus On Marijuana And Health This Week – https://t.co/aPZczm3X75
— Senator John Cornyn (@JohnCornyn) October 21, 2019
The senator made clear he’s skeptical about marijuana’s health benefits.
“There’s no shortage of people who claim that marijuana has endless health benefits and can help patients struggling from everything from epilepsy to anxiety to cancer treatments,” he said. “This reminds me of some of the advertising we saw from the tobacco industry years ago where they actually claimed public health benefits from smoking tobacco, which we know as a matter of fact were false and that tobacco contains nicotine, an addictive drug, and is implicated with cancers of different kinds.”
“We’re hearing a lot of the same happy talk with regard to marijuana and none of the facts that we need to understand about the public health impact of marijuana use,” he said.
While Cornyn recognized there’s significant support for cannabis reform, he said that ” for the number of voices in support of legalization, there are even more unanswered questions about both the short- and long-term public health effects.”
He expressed concern about increased levels of THC concentration in cannabis products and stated that it’s “true that for some people that marijuana can indeed be addictive.”
“There’s simply a lack of scientific evidence to determine the link between marijuana and various health risks, and that’s something I would think Congress and the American people would want to know before we proceed further down this path,” Cornyn said. “We don’t know enough about how this could impair cognitive function or capacity or increase the risk of mental illness or perhaps serve as a gateway for other drugs that are even more damaging to the health of a young person.”
The senator made similar remarks during a conversation with a former White House drug czar in August. He said it was important to address the public health impacts of cannabis before moving forward with legislation that would protect banks that service marijuana businesses from being penalized by federal regulators.
“With increasing use and a growing number of states giving the green light for marijuana use, we need better answers,” he said.
The surgeon general and the director of the National Institute on Drug Abuse, along with several academics, are scheduled to testify at Wednesday’s hearing.
Photo courtesy of C-SPAN.
Michael J. Fox Parkinson’s Foundation Urges Congress To Pass Three Marijuana Research Bills
A leading advocacy group that’s dedicated to finding treatment options for Parkinson’s disease is backing three pieces of marijuana research legislation in Congress.
The Michael J. Fox Foundation (MJFF)—named after the actor, who has Parkinson’s and established the nonprofit—said last week that lifting barriers to cannabis research, including rescheduling the plant under the Controlled Substances Act (CSA), is necessary to promote studies verifying marijuana’s potential therapeutic benefit for conditions such as Parkinson’s patients.
“The MJFF supports increased access to cannabis for medical research. Congress has begun to recognize this need, and there are several bills in the U.S. House and Senate designed to remove barriers that impede safe and legal access to cannabis by medical researchers,” the foundation said on its website. “The MJFF public policy team is tracking these bills and working to educate members of Congress and their staff on their importance to the Parkinson’s community.”
MJFF said it’s in favor of three marijuana bills, which would accomplish the following:
—Require the Justice Department to approve additional manufacturers for research-grade cannabis.
—Protect research institutions that conduct studies on marijuana.
—Authorize the U.S. Department of Veterans Affairs (VA) to inform patients about opportunities to participate in federally authorized cannabis studies.
—Require VA to conduct studies into the therapeutic potential of marijuana in the treatment of various conditions that commonly afflict veterans such as chronic pain and post-traumatic stress disorder.
—Reschedule marijuana from Schedule I to Schedule III under the CSA.
—Free up universities to conduct studies on cannabis by removing certain regulatory requirements.
In a letter to the Senate sponsor of that last piece of legislation, Sen. Dick Durbin (D-IL), in June, the foundation stated that marijuana’s current classification under federal law and the inadequate quality of cannabis grown at the only federally authorized manufacturing facility has meant that “researchers do not have the proper materials to conduct the necessary research.”
The foundation noted that it has submitted comments to the Food and Drug Administration arguing in favor of rescheduling in 2018 and 2019. It also applauded the Drug Enforcement Administration for announcing that it would take steps to approve additional federal cannabis farms for research.
“Current policies hinder comprehensive medical research on cannabis, making it difficult to generate the evidence needed for clear recommendations,” Andrew Koemeter-Cox, MJFF’s associate director of research programs, said. “This is especially problematic when some products may be unsafe for human use and have the potential for adverse interactions with other medications.”
Ted Thompson, the nonprofit’s senior vice president of public policy, said that removing barriers to research “is one way in which Congress can help scientific researchers determine what the benefits of medical cannabis might be for Parkinson’s disease.”
“Our role on the public policy team is to work with Congress and the administration to ensure there is access and funding for research and care initiatives that can benefit people living with Parkinson’s and, right now, that includes access to medical cannabis for research,” he said.
Photo courtesy of Brian Shamblen.